Eli Lilly's Data Demand Threatens 340B Discounts for Hospitals

Eli Lilly and Company has made good on its threat to cut off 340B discount pricing for hospitals that refuse to comply with its new claims data submission policy. The move, which took effect earlier this month, has sparked outrage among hospital industry groups, who argue that the policy is unlawful and places an undue burden on providers.

Lilly implemented the policy on February 1, requiring hospitals to submit detailed claims data to maintain eligibility for discounted drugs under the 340B program. The company warned that those failing to comply would lose access to these discounts. On June 8, Lilly followed through on its threat, instructing wholesalers to revoke 340B pricing for an unspecified number of hospitals.

Maureen Testoni, President and CEO of 340B Health, an industry group representing over 1,600 hospitals participating in the drug discount program, expressed deep concern. “Eli Lilly has cut off 340B pricing for drugs hospitals order and dispense directly to their patients,” she stated. “These dispenses are at the very core of the 340B program, and Eli Lilly’s refusal to provide 340B pricing to hospitals that do not surrender to its sweeping claims data demands does not represent a legitimate offer by Lilly to sell drugs to covered entities at the 340B price.”

The Stakeholders' Perspectives

The 340B program is designed to help safety-net hospitals and clinics provide more affordable medications to low-income and uninsured patients. By offering substantial discounts on outpatient drugs, the program aims to reduce healthcare costs for vulnerable populations. However, Lilly's new policy has been widely criticized by hospital groups for imposing significant administrative burdens.

Testoni reiterated the hospital industry’s broader position that Lilly’s policy and revoked discounts violate the law and represent an unprecedented attempt to rewrite 340B rules without congressional approval. “77% of Medicaid care and 67% of uncompensated care in this country is provided by 340B hospitals,” she emphasized. “We call on the government's Health Resources and Services Administration (HRSA) to take enforcement action immediately to restore access.”

Lilly, however, defends its policy as necessary for ensuring transparency and preventing misuse of the 340B program. The company argues that the data submission requirement will help identify and address potential issues, such as overcharging or improper use of discounted drugs.

Why It Matters

The conflict between Eli Lilly and hospitals highlights a broader issue in healthcare: the balance between regulatory oversight and pharmaceutical industry practices. The 340B program is a lifeline for many safety-net providers, enabling them to offer essential services to underserved communities. If more drugmakers follow Lilly's lead, the financial strain on these institutions could become unsustainable, potentially leading to reduced access to care for vulnerable patients.

The situation also underscores the need for clear and enforceable regulations governing the 340B program. While transparency is important, the administrative burden placed on hospitals must be manageable. The HRSA, which oversees the 340B program, faces a critical challenge in balancing these competing interests to ensure that the program continues to serve its intended purpose.

As the debate intensifies, the healthcare community and policymakers will need to work together to find a solution that protects both patient access and program integrity. The outcome of this conflict could have far-reaching implications for how drug discounts are managed and whether safety-net providers can continue to provide essential care to those who need it most.